Mandate

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.

Calliditas Therapeutics is a biopharma company listed on Nasdaq Stockholm and on the Nasdaq Global Select Market in the US focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The total value of the offer amounts to approximately SEK 11,164 million, based on the total number of outstanding shares in Calliditas Therapeutics. Vinge advises Calliditas Therapeutics.

Vinge’s team has mainly consisted of Dain Hård Nevonen, Linnéa Sellström, William Kåge and Benjamin Vafaeian (Capital Markets and Public M&A) and Daniel Wendelsson (FDI).

Related

Vinge advises L5 Navigation in connection with the acquisition of Lundaman Instrument

L5 Navigation Systems AB has acquired the shares in Lundaman Instrument AB. Lundaman develops and supplies weighing systems for wheel loaders and forklift trucks, focusing on the construction, recycling, industrial and materials handling sectors.
May 13, 2026

Vinge advises Aonic in connection with the issuance of subsequent senior secured bonds of EUR 25 million

Vinge has advised Aonic AB (publ) in connection with the issuance of subsequent senior secured bonds of EUR 25 million, and parallel written procedure to increase the bond framework to EUR 150 million.
May 12, 2026

Vinge advises Consolid Equity and other sellers on the sale of Sertion to Altor

Vinge has advised Consolid Equity and other sellers on the sale of the Sertion Group to Altor. In connection with the transaction, entrepreneurs and management will reinvest and remain as key owners, partnering with Altor to accelerate the group’s next phase of growth across existing markets and into new geographies.
May 11, 2026